Saltar al contenido
Merck

Molecular basis of impaired glycogen metabolism during ischemic stroke and hypoxia.

PloS one (2014-05-27)
Mohammed Iqbal Hossain, Carli Lorraine Roulston, David Ian Stapleton
RESUMEN

Ischemic stroke is the combinatorial effect of many pathological processes including the loss of energy supplies, excessive intracellular calcium accumulation, oxidative stress, and inflammatory responses. The brain's ability to maintain energy demand through this process involves metabolism of glycogen, which is critical for release of stored glucose. However, regulation of glycogen metabolism in ischemic stroke remains unknown. In the present study, we investigate the role and regulation of glycogen metabolizing enzymes and their effects on the fate of glycogen during ischemic stroke. Ischemic stroke was induced in rats by peri-vascular application of the vasoconstrictor endothelin-1 and forebrains were collected at 1, 3, 6 and 24 hours post-stroke. Glycogen levels and the expression and activity of enzymes involved in glycogen metabolism were analyzed. We found elevated glycogen levels in the ipsilateral hemispheres compared with contralateral hemispheres at 6 and 24 hours (25% and 39% increase respectively; P<0.05). Glycogen synthase activity and glycogen branching enzyme expression were found to be similar between the ipsilateral, contralateral, and sham control hemispheres. In contrast, the rate-limiting enzyme for glycogen breakdown, glycogen phosphorylase, had 58% lower activity (P<0.01) in the ipsilateral hemisphere (24 hours post-stroke), which corresponded with a 48% reduction in cAMP-dependent protein kinase A (PKA) activity (P<0.01). In addition, glycogen debranching enzyme expression 24 hours post-stroke was 77% (P<0.01) and 72% lower (P<0.01) at the protein and mRNA level, respectively. In cultured rat primary cerebellar astrocytes, hypoxia and inhibition of PKA activity significantly reduced glycogen phosphorylase activity and increased glycogen accumulation but did not alter glycogen synthase activity. Furthermore, elevated glycogen levels provided metabolic support to astrocytes during hypoxia. Our study has identified that glycogen breakdown is impaired during ischemic stroke, the molecular basis of which includes reduced glycogen debranching enzyme expression level together with reduced glycogen phosphorylase and PKA activity.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Alcohol etílico puro, 200 proof, for molecular biology
Sigma-Aldrich
Alcohol etílico puro, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
Alcohol etílico puro, 200 proof, HPLC/spectrophotometric grade
Sigma-Aldrich
Alcohol etílico puro, 200 proof, meets USP testing specifications
Sigma-Aldrich
Alcohol etílico puro, 190 proof, for molecular biology
Sigma-Aldrich
Alcohol etílico puro, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
Etanol, ACS reagent, prima fine spirit, without additive, F15 o1
Sigma-Aldrich
Etanol, BioUltra, for molecular biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Sigma-Aldrich
Alcohol etílico puro, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
Calcein-AM, suitable for fluorescence, BioReagent, ≥90% (HPLC)
Sigma-Aldrich
Etanol, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Supelco
Ethanol solution, certified reference material, 2000 μg/mL in methanol
Sigma-Aldrich
Etanol, purum, absolute ethanol, denaturated with 2% 2-butanone, A15 MEK1, ≥99.8% (based on denaturant-free substance)
Supelco
Ethanol solution, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
Alcohol etílico puro, 190 proof, meets USP testing specifications
Sigma-Aldrich
Calcein-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
USP
Etanol, United States Pharmacopeia (USP) Reference Standard
Supelco
Etanol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
1,4-Dideoxy-1,4-imino-D-arabinitol hydrochloride, enzyme inhibitor
Sigma-Aldrich
Calcein AM solution, 4 mM in DMSO, ≥90% (HPLC), solution